Publications
5677 Results
- Journal / Conference
- Melanoma Bridge Meeting (Dec 1-3.2-22, Napoli, Italy), oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
EXPLORATORY ANALYSES FROM SWOG S1801
- Journal / Conference
- ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Leukemia
- Study Number(s)
- MYELOMATCH
Umbrella Trial in Myeloid Malignancies: the myeloMATCH National Clinical Trials Network Precision Medicine Initiative
- Journal / Conference
- Supportive Care in Cancer Dec 31;31(1):93
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID36585488
- PMC
- PMC9803880
- Study Number(s)
- S1204
Antiviral Therapy Use and Related Outcomes in Patients with Cancer and Viral Infections: Results from SWOG S1204
- Journal / Conference
- Nature Communications Sep 19;13(1):5478
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36117191
- PMC
- PMC9482920
- Study Number(s)
- CTSU/C80405
ARID1A mutations induce an EGFR-like signature and confer intrinsic and acquired resistance to cetuximab treatment in colon cancer
- Journal / Conference
- Bladder Cancer, volume 8; issue 4
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0337
Paper Alert—Implementing a New Standard of Care [Commentary]
- Journal / Conference
- JAMA Network Open Nov 1;5(11):e2241720
- Year
- 2022
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID36367721
- PMC
- PMC9652759
- Study Number(s)
- S1200
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial
- Journal / Conference
- Journal of the Comprehensive Cancer Network Oct;20(10):1080-1090
- Year
- 2022
- Research Committee(s)
- Cancer Survivorship
- PMID
- PMID36240847
NCCN Guidelines® Insights: Survivorship, Version 1.2022
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9559); American Society of Clinical Oncology
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/EA6134
Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
- Journal / Conference
- International Kidney Cancer Symposium (November 4-5, 2022, Austin, TX), TIPS, Poster Board F1 Abstract 49
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A031801
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
- Journal / Conference
- JADPRO Jan/Feb, Vol 14, No 1 (JADPRO Live Conference 2022 (October 20 thru 23, 2022, Aurora, CO))
- Year
- 2022